Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
High PD1 mRNA levels tied to anti-PD1 monotherapy response
Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.
Key clinical point: Expression of programmed death-1 (PD1) mRNA may predict outcomes after anti-PD1 therapy across cancer types.
Major finding: The overall response rate was 51.5% for the patients who had PD1-high tumors, versus 23.8% for the remaining tumors (P less than .001).
Study details: Evaluation of PD1 mRNA expression in tumor samples from 117 patients treated with either nivolumab or pembrolizumab monotherapy.
Disclosures: The work was partially sponsored by the Instituto de Salud Carlos III, Spanish Society of Medical Oncology, Banco Bilbao Vizcaya Argentaria Foundation, Pas a Pas, Save the Mama, and the Breast Cancer Research Foundation. One author disclosed an advisory role with Nanostring Technologies.
Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.